LXN

Across TCGA pan-cancer cohorts, LXN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LXN data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LXN mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LXN expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where LXN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	0.587	1.000	.006	16	view →
PDAC	OS	Median	IV	0.951	0.381	.006	10	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	8	view →
GBM	DFS	Quartile	All	0.430	0.248	.011	2	view →
HNSC	OS	Median	III,IV	0.573	0.755	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LXN–LSCC (OS)

Open the LSCC breakdown →